Skip to main content

Lonza extends services with new factory

| News

Lonza extends services with new factory

03.07.2019

Basel-based chemicals and pharmaceuticals company Lonza acquires facility for sterile drug manufacturing from Novartis. With the new production facility in Stein AG Lonza will extend its service offering, as well as taking on the existing employees and providing investment in Basel.

Flags. (Img: Lonza)

According to a press release, Lonza wants to use the facility for its Drug Product Services (DPS). DPS will manufacture in Stein for the existing owner of the factory the pharma company Novartis, which is also based in Basel. It is the first facility for Lonza’s Drug Product Services (DPS) to cover sterile manufacturing for clinical production and commercial launches. Hanns-Christian Mahler, Head of Drug Products Services, Lonza Pharma & Biotech: “After the acquisition the new manufacturing facility in Stein will be our first sterile product fill and finish facility and will work in close synergy with our existing facility in StückiPark in Basel.”

Acquisition will be completed in the next few months after a binding contractual commitment has been agreed. Novartis previously used the facility as a competence center for sterile drug production and for clinical trials. The site includes cleanroom areas, offices, lab space, utilities and storage. Lonza will take on both the management and the staff.

For DPS the acquisition is further step in its growth strategy. DPS was formed at the end of 2016. As a result of the strong demand from the market the sites in Basel and Visp VS will be expanded. Thus, from 2020 DPS wants to “expand development and testing labs into a larger building in Basel “.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.